All In Biotech

Drug Trial Radar · NCT00463606

A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With Dyslipidemia

A 12-week, Multicenter, Randomized, Double-Blind, Parallel-Group Study of the Combination of ABT-335 and Rosuvastatin Compared to ABT-335 and Rosuvastatin Monotherapy in Subjects With Type IIa and IIb Dyslipidemia

Last checked: Nov 20, 2026Latest source record: Oct 3, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 760 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

760

Actual

Start

Apr 2007

Primary completion

Feb 2008

Study completion Feb 2008

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Apr 20, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of ABT-335 and rosuvastatin calcium combination therapy to monotherapy in subjects with dyslipidemia.

Conditions

  • Hypercholesterolemia
  • Dyslipidemia

Interventions

  • ABT-335 and rosuvastatin calciumDrug

    ABT-335 135 mg in combination with rosuvastatin calcium 5 mg administered orally, once daily for 12 weeks

  • ABT-335Drug

    ABT-335 135 mg monotherapy administered orally, once daily for 12 weeks

  • rosuvastatin calciumDrug

    Rosuvastatin calcium 5 mg monotherapy administered orally, once daily for 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Percent Change From Baseline to the Final Visit in High-density Lipoprotein Cholesterol (HDL-C) (Full Analysis Set)Time frame: Baseline to 12 Weeks
  2. Mean Percent Change From Baseline to the Final Visit in Triglycerides (Full Analysis Set)Time frame: Baseline to 12 Weeks
  3. Mean Percent Change From Baseline to the Final Visit in Low-density Lipoprotein Cholesterol (LDL-C) (Full Analysis Set)Time frame: Baseline to 12 Weeks

Locations

168 sites in 1 country. Site status is shown where the registry gives one.

  • Site Reference ID/Investigator# 5469

    Birmingham, Alabama

  • Site Reference ID/Investigator# 4428

    Birmingham, Alabama

  • Site Reference ID/Investigator# 4985

    Birmingham, Alabama

  • Site Reference ID/Investigator# 4493

    Huntsville, Alabama

  • Site Reference ID/Investigator# 4510

    Huntsville, Alabama

  • Site Reference ID/Investigator# 4431

    Ozark, Alabama

  • Site Reference ID/Investigator# 4519

    Tuscaloosa, Alabama

  • Site Reference ID/Investigator# 4395

    Chandler, Arizona

  • Site Reference ID/Investigator# 4483

    Gilbert, Arizona

  • Site Reference ID/Investigator# 4411

    Scottsdale, Arizona

  • Site Reference ID/Investigator# 4417

    Little Rock, Arkansas

  • Site Reference ID/Investigator# 4702

    Anaheim, California

  • Site Reference ID/Investigator# 5593

    Chula Vista, California

  • Site Reference ID/Investigator# 4503

    Concord, California

  • Site Reference ID/Investigator# 4530

    Encinitas, California

  • Site Reference ID/Investigator# 4458

    Fair Oaks, California

  • Site Reference ID/Investigator# 4542

    Fresno, California

  • Site Reference ID/Investigator# 4574

    Fresno, California

  • Site Reference ID/Investigator# 4441

    Lincoln, California

  • Site Reference ID/Investigator# 4432

    Long Beach, California

  • Site Reference ID/Investigator# 5579

    Los Angeles, California

  • Site Reference ID/Investigator# 4980

    Norwalk, California

  • Site Reference ID/Investigator# 4392

    Sacramento, California

  • Site Reference ID/Investigator# 4896

    Sacramento, California

  • Site Reference ID/Investigator# 5582

    San Diego, California

  • Site Reference ID/Investigator# 6236

    West Hills, California

  • Site Reference ID/Investigator# 4442

    Aurora, Colorado

  • Site Reference ID/Investigator# 4419

    Colorado Springs, Colorado

  • Site Reference ID/Investigator# 4391

    Waterbury, Connecticut

  • Site Reference ID/Investigator# 4401

    Coral Gables, Florida

  • Site Reference ID/Investigator# 4453

    Fort Lauderdale, Florida

  • Site Reference ID/Investigator# 4490

    Holly Hill, Florida

  • Site Reference ID/Investigator# 4420

    Hollywood, Florida

  • Site Reference ID/Investigator# 5011

    Jacksonville, Florida

  • Site Reference ID/Investigator# 4444

    Jacksonville, Florida

  • Site Reference ID/Investigator# 4399

    Jupiter, Florida

  • Site Reference ID/Investigator# 4433

    Kissimmee, Florida

  • Site Reference ID/Investigator# 4469

    Largo, Florida

  • Site Reference ID/Investigator# 4525

    Melbourne, Florida

  • Site Reference ID/Investigator# 4477

    Miami, Florida

Showing 40 of 168 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.